Physician profile
Amy E Hughes
NPI 1437262086
$878.89
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $184 · 2021: $11.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $247.95 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2019 | |
| Janssen Biotech, INC. | $123.47 | 2019 | |
| Seagen INC. | $111.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.70 | 2019-2020 | |
| Array Biopharma INC | $21.94 | 2019 | |
| Glaxosmithkline, LLC. | $21.78 | 2020 | |
| Rigel Pharmaceuticals, INC. | $21.25 | 2019 | |
| Amgen INC. | $20.77 | 2019 | |
| Agios Pharmaceuticals, INC. | $17.61 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.00 | 2019 | |
| Heron Therapeutics, INC. | $16.15 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.68 | 2019 | |
| Pfizer INC. | $14.57 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.83 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $13.48 | 2019 | |
| Astellas Pharma US INC | $13.48 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.